Comparing the Renal Effect of Dipeptidyl-peptidase 4 Inhibitors and Sulfonylureas
Status:
Completed
Trial end date:
2018-02-28
Target enrollment:
Participant gender:
Summary
Dipeptidyl peptidase 4 (DPP-4) inhibitors and sulfonylureas have been extensively used in the
treatment of type 2 diabetes mellitus (T2DM). Although both medications effectively lower
plasma glucose levels, differences may exist in their pharmacokinetics and effect on the
kidney. In the context of diabetic kidney disease, DPP-4 inhibitors may confer renal
protection through several putative mechanisms. In contrast, sulfonylureas are associated
with weight gain and cardiac dysfunction, which may adversely influence kidney function.
The investigators hypothesize that DPP-4 inhibitors and sulfonylureas may have a different
effect on the diabetic kidney. This study compares the effect of DPP-4 inhibitors and
sulfonylureas on urinary albumin excretion in patients with newly diagnosed T2DM.